Octanoic Acid
Small molecule
Octanoic Acid is one of 45 small molecule programs targeting Tremor. It is currently in development.
2
Indications
3
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
46 competitors in Essential Tremor
#DrugCompanyPhaseTrials
1Namenda
AbbVieApproved
Epidiolex
Jazz PharmaceuticalsApproved
Marinol
Alnylam PharmaceuticalsApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Topamax
WWim Janssens
Approved
Mirapex
Boehringer IngelheimPhase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Xyrem
Jazz PharmaceuticalsPhase 2
Zonegran
AAzurity Pharmaceuticals
Phase 2
Fycompa
CCatalyst Biosciences
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Essential Tremor2 trials
Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1/2·NCT00848172·29 enrolled
Octanoic Acid for Essential Tremor
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT01468948·18 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Octanoic Acid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]